May 2026 is an important month for medical device manufacturers preparing or maintaining market access in the European Union and Canada.

In the EU, the first four EUDAMED modules become mandatory on May 28, 2026. In Canada, Health Canada’s move toward structured electronic submissions means manufacturers need to be more disciplined in how medical device licence applications, amendments, and supporting technical documentation are prepared.

For manufacturers, the practical message is simple: regulatory data, UDI information, certificates, technical documentation, and submission packages need to be consistent, complete, and ready for review.

1. EU: EUDAMED mandatory use begins May 28, 2026

The European Commission confirmed that, as of May 28, 2026, the first four EUDAMED modules are mandatory to use:

  • Actor Registration
  • UDI/Device Registration
  • Notified Bodies and Certificates
  • Market Surveillance

This follows the publication of the Commission Decision declaring the functionality of the first four modules and triggering the six-month transition period under Regulation (EU) 2024/1860.

For manufacturers, this is not only a database activity. EUDAMED data needs to align with technical documentation, certificates, UDI records, labeling, economic operator information, and post-market surveillance processes.

Practical takeaways

Manufacturers should confirm that:

  • Actor registration and SRN information are current
  • Basic UDI-DI and UDI-DI data are accurate
  • Certificate information is consistent with notified body records
  • Labeling and technical documentation match device registration data
  • Internal responsibility for EUDAMED maintenance is clearly assigned
  • Procedures define how EUDAMED records are updated when device, labeling, certificate, or economic operator information changes

The compliance risk is not just missing the EUDAMED deadline. The larger risk is inconsistency between EUDAMED, labeling, certificates, technical documentation, UDI records, and post-market surveillance files.

2. Canada: REP/CESG and structured submission readiness are now the practical baseline

Health Canada has continued moving toward more structured medical device submissions. The Regulatory Enrolment Process, or REP, and the Common Electronic Submission Gateway, or CESG, are now part of the practical submission environment for medical device regulatory transactions.

Health Canada also uses the IMDRF Table of Contents format for medical device regulatory activities. This structure applies to new and amendment Class II, III, and IV medical device licence applications, private label applications, fax-back applications, deficiency responses, clarification responses, and certain post-market responses.

This means manufacturers should not treat Canadian medical device submissions as only a form-filling exercise. The application package needs to be structured, internally consistent, and supported by the right evidence.

Practical takeaways

Before preparing a Canadian Medical Device Licence application or amendment, manufacturers should confirm:

  • Device classification
  • Correct licence application pathway
  • Required application forms
  • REP/CESG readiness
  • IMDRF Table of Contents structure
  • Safety and effectiveness evidence
  • Labeling and instructions for use
  • Risk management documentation
  • Clinical evidence rationale
  • Quality management system certification status
  • Consistency between claims, intended use, labeling, and supporting evidence

The application form is only one part of the process. The supporting documentation still needs to demonstrate that the device is safe, effective, properly labeled, and supported by adequate technical and quality system evidence.

Bottom line

May 2026 is a practical readiness month.

In the EU, EUDAMED mandatory use begins on May 28, 2026. In Canada, structured electronic submission expectations continue to make submission planning more disciplined.

Manufacturers should use this period to check whether their regulatory data, UDI records, technical documentation, certificates, labeling, and submission packages are aligned.

The key question is not only whether the company can submit. The better question is whether the information being submitted is complete, consistent, and defensible.

How Panabistics can help

Panabistics supports medical device companies with regulatory strategy, global market access, Health Canada medical device licensing, EU MDR/IVDR support, UDI planning, technical documentation, QMS readiness, FDA submissions, UK market access planning, and post-market compliance.

If your organization is preparing a new submission, updating technical documentation, responding to regulatory questions, or assessing readiness for EU or Canadian market access, Panabistics can help translate regulatory requirements into practical action. Contact us.

References

  • European Commission: EUDAMED first four modules mandatory use from May 28, 2026 — health.ec.europa.eu
  • Health Canada: Mandatory use of the Regulatory Enrolment Process for medical devices — canada.ca
  • Health Canada: IMDRF Table of Contents for medical device applications — canada.ca